Our company has transformed from Evolve Biosystems® to Infinant Health™. Learn More.

Bifidobacterium longum subsp. infantis EVC001.
The strain that matters.

The past several decades have seen a significant increase in infant gut dysbiosis, along with a rapid rise in the incidence of eczema, allergies, obesity, and diabetes.101533 Research indicates these two events may be related—and solving gut dysbiosis can make an impact.

However, choosing an effective probiotic for infant use requires selecting the right bacterial strain, in combination with the right food source, given at the right time in infant development.  Evivo® (activated Bifidobacterium longum subsp. infantis EVC001, Actibif®) in combination with human milk, is clinically proven to effectively reduce the abundance of potentially pathogenic bacteria, and provide functional, measurable benefits to the infant gut within days.

View this informative video from the International Scientific Association for Probiotics and Prebiotics (ISAPP) on differences in probiotic strain bacteria.

The Right Strain

Research on the gut microbiome has led to the identification of hundreds of types of bacteria. Bifidobacterium is one of the most abundant when it comes to the infant gut microbiome, but of the many Bifidobacterium species and subspecies that exist, only Bifidobacterium longum subsp. infantis (B. infantis) is uniquely adapted to utilize human breastmilk to colonize and provide benefit to the infant gut. 

Isolated from a healthy breastfed infant, Evivo is an activated strain of Bifidobacterium longum subsp. infantis shown to efficiently utilize human breastmilk as a fuel source. In turn, B. infantis EVC001 rapidly colonizes the infant gut and suppressing the growth of pathogenic bacteria. Evivo is activated and able to metabolize breastmilk better than any other strain of probiotic bacteria. 

A diagram of gut dysbiosis showing how Bifidobacterium longum subsp. infantis thrives in the infant gut.

The Right Food 

There are hundreds of complex carbohydrates found naturally in breastmilk, called human milk oligosaccharides (HMOs).  Bifidobacterium longum subsp. infantis is the only bacterium that possesses all enzymes necessary to break down the chemical bonds in HMOs. This gives B. infantis a significant competitive advantage in the infant gut microbiome, providing it the ability to colonize and outcompete other gut bacteria.

Evivo is an activated form of B. infantis, which means it is ready to metabolize HMOs immediately upon feeding to the infant, allowing it to rapidly colonize the infant gut and provide functional, measurable benefits within days.

The Right Time

The infant gut microbiome develops rapidly during the first year of life, beginning with inoculation of bacteria during labor and delivery, and the gradual colonization of bacteria during the first weeks of life.18  In parallel, the first months of life are also a period of rapid immune and metabolic development, during which the gut microbiome plays a significant role. Bifidobacterium longum subsp. infantis has specifically been identified as a key bacterium that provides an important functional role in the infant gut during this time.31 However, due to common medical practices such as C-section delivery and antibiotic use, the majority of infants born today do not naturally acquire B. infantis during this early and important window of development. 

Choosing a probiotic for infant use requires the selection of a bacterium that is appropriate for both the developmental stage, as well as for the available food source.   Evivo, in combination with HMOs, is clinically proven to effectively and efficiently restore colonization of ifidobacterium longum subsp. infantis to the infant gut microbiome and suppress the abundance of pathogenic bacteria. Feeding Evivo along with breastmilk during the first 6 months of life is a key component to establishing a healthy infant gut microbiome—setting a foundation for lifelong health.


Speak to a Sales Director